Patents by Inventor Nigel Pelham Clinton Walker

Nigel Pelham Clinton Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD39 antibodies and use thereof
    Patent number: 11970543
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 30, 2024
    Assignees: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, JijIe Gu
  • ANTI-CD39 ANTIBODIES AND USE THEREOF
    Publication number: 20240034803
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 1, 2024
    Applicants: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, Jijie Gu
  • Antibodies to TIGIT
    Patent number: 11820824
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Kelsey Sivick Gauthier, Nigel Pelham Clinton Walker, Xiaoning Zhao, John Lippincott
  • ANTIBODIES TO TIGIT
    Publication number: 20220064294
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: June 1, 2021
    Publication date: March 3, 2022
    Inventors: Kelsey Sivick GAUTHIER, Nigel Pelham Clinton WALKER, Xiaoning ZHAO, John LIPPINCOTT
  • Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 9920134
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: March 20, 2018
    Assignee: AMGEN INC.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terrence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 9493576
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: November 15, 2016
    Assignee: AMGEN INC.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 9056915
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: June 16, 2015
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 9045547
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: June 2, 2015
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20150087819
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Inventors: SIMON MARK JACKSON, NIGEL PELHAM CLINTON WALKER, DEREK EVAN PIPER, BEI SHAN, WENYAN SHEN, JOYCE CHI YEE CHAN, CHADWICK TERENCE KING, RANDAL ROBERT KETCHEM, CHRISTOPHER MEHLIN, TERESA ARAZAS CARABEO, QIONG CAO
  • ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20150031870
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 29, 2015
    Inventors: SIMON MARK JACKSON, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357852
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357851
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357854
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357850
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357853
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8889834
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 18, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8883983
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 11, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8871914
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 28, 2014
    Assignee: Amgen, Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8871913
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 28, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
    Patent number: 8859741
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 14, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo